APO-E Antibody | 7333 | ProSci
Reactivity: Human, Mouse, Rat
Homology: Predicted species reactivity based on immunogen sequence: Pig: (78%)
Immunogen: APO-E antibody was raised against a 19 amino acid peptide near the carboxy terminus of human APO-E.
The immunogen is located within amino acids 220 - 270 of APO-E.
Research Area: Neuroscience
Tested Application: E, WB, IHC-P, IF
Application: APO-E antibody can be used for detection of APO-E by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human and mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Positive Control 1: Cat. No. 1303 - Human Brain Tissue Lysate
Positive Control 2: Cat. No. 10-201 - Human Liver Tissue Slide
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: Predicted: 35 kDa
Observed: 34 kDa
Purification: APO-E Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
Buffer: APO-E Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Condition: APO-E antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
Alternate Name: APO-E Antibody: AD2, LPG, LDLCQ5, Apolipoprotein E, Apo-E
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: APO-E Antibody: Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E (APO-E) , a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. Defects in APO-E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III) , in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants.
E, IF, IHC-P, WB
Human, Mouse, Rat